Telehealth and cognitive behavioral therapy for insomnia …

Skye Margolies PhD

Sleep Disorders

Updated 07.14.2023
Released 07.14.2023
Expires For CME 07.14.2026

Telehealth and cognitive behavioral therapy for insomnia (CBT-I0)

Author: Skye Margolies PhD

See Contributor Disclosures

Editor: Bradley V Vaughn MD

Telehealth and cognitive behavioral therapy for insomnia (CBT-I0)

In This Article

Quick Link

Introduction

Overview

Chronic insomnia is a sleep disorder characterized by a long-term pattern of difficulty with sleep initiation or maintenance and perceived daytime impairment or distress as a result of poor sleep quality. Worldwide estimates suggest that approximately 30% of the population reports one or more symptoms of chronic insomnia (46). Current medical guidelines recommend cognitive-behavioral therapy for insomnia (CBT-I) as a first-line treatment for chronic insomnia based on a strong body of research (11). CBT-I is a multi-component treatment that both addresses psychological, behavioral, and physiological factors that perpetuate insomnia and focuses on establishing more effective patterns of behavior and thinking to optimize sleep quality. Despite being the treatment of choice for chronic insomnia, CBT-I availability is limited due to several barriers. These barriers include the absence of clinicians trained in CBT-I; lack of awareness by clinicians to screen for insomnia or to refer for CBT-I; patient issues, including lack of awareness or engagement; as well as systems issues associated with access and economic burden (ie, locations of clinics, insurance reimbursement, missing work to attend appointments) (30). In addition, integration of mental health services in medical settings, where sleep patients are seen, faces structural and financial barriers that currently limit widespread application of this evidence-based approach. These access barriers are accentuated for minorities and the underserved.

Efforts to overcome such barriers in both medical and mental health settings involve the use of sleep telemedicine. Over the past 2 decades, there has been a growing body of research examining the potential benefits of teletherapy and, specifically, cognitive-behavioral therapy delivered via telehealth (22; 15). The rapid and widespread adoption of telehealth at the beginning of the COVID-19 pandemic has accelerated this research and demonstrated effectiveness as well as patient acceptability (06). These efforts have extended to the treatment of insomnia, and studies have demonstrated the effectiveness of an “ehealth” approach to CBT-I as a patient-centered alternative to face-to-face treatment, with the benefit of being able to reach a larger portion of the patient population that might not otherwise benefit from this treatment.

Key points

	• Cognitive-behavioral therapy for insomnia (CBT-I) is a first-line treatment for insomnia.
	• Access to personnel trained in CBT-I is limited for several reasons.
	• Telehealth offers a promising alternative modality for delivering CBT-I and expanding access.
	• CBT-I delivered via telehealth broadly has strong empirical support. Future research is needed to determine how to best triage and personalize these innovative and promising modalities that expand access to care and optimize sleep health.

Discussion

Cognitive behavioral therapy for insomnia (CBT-I) is an evidence-based insomnia treatment that leads to sustained benefit by addressing perpetuating behaviors and beliefs (51). Behavioral strategies include consolidating sleep and strengthening the association between the bedroom and sleep. Cognitive strategies involve sleep education so as to demystify any myths or beliefs that might perpetuate poor sleep. Relaxation and mindfulness techniques are also implemented to decrease cognitive and physiological hyperarousal that is frequently part of the insomnia symptom profile. Advantages to using CBT-I compared to medications include no known side effects, lower cost, greater efficiency, and durability (42). The American Academy of Sleep Medicine and the American College of Physicians recommend CBT-I as a first-line treatment for insomnia over medication, even in the context of psychological and medical comorbidity (44; 11).

Despite such clinical indications and professional endorsement, the uptake and widespread dissemination and implementation of CBT-I in medical settings is limited, and the gap between this gold standard treatment and clinical practice persists. Patient and physician awareness, lack of qualified CBT-I clinicians, and poor geographical distribution of providers trained in CBT-I continue to be major impediments to widespread usage (54). In addition, integration of mental health services in medical settings face operational and economic barriers that currently limit widespread application of this evidence-based approach. These barriers to access are accentuated for minorities and the underserved who often suffer more severe insomnia consequences. The implications of this lack of access are an individual and public health concern. The cost of untreated insomnia includes, but is not limited to, increased absenteeism, morbidity, disability, and healthcare expenses (07; 41). These barriers to treatment are well documented and have motivated a growing body of research examining alternative adaptations for disseminating CBT-I more widely. Innovations such as briefer behavioral treatments, group therapy, stepped care approaches, expanding training opportunities, and non-face-to-face options, including phone, bibliotherapy, and self-help options, have demonstrated effectiveness in improving sleep and are not reliant on traditional (and limited) in-person treatment (23; 38). Telehealth options also address some of these barriers, and the U.S. Department of Health and Human Services stresses the importance of “health internet technology” as a means of improving access to healthcare. Sleep telemedicine offers another opportunity for increasing access to this gold standard treatment.

Sleep telemedicine

Sleep telemedicine is a growing field of research and clinical interest and has been the subject of several reviews exploring its effectiveness and viability as an alternative option for treating insomnia (48; 52; 49; 50). Defined in a 2015 AASM position paper (updated in 2020 to reflect lessons learned from the COVID-19 pandemic) as “use of sleep-related medical information exchanged from one site to another via electronic communications to improve a patient’s health,” sleep telemedicine incorporates different modalities, including telephone, video, internet, or smartphone applications.

Table 1. Types of TeleHealth and Telemedicine

Method	Synchronous versus Asynchronous	Description
Telephone	Synchronous	Audio only interaction
Live video conferencing	Synchronous	Video and audio real-time interaction
Asynchronous video	Asynchronous	Video and audio stored and then sent for later reply
Software apps, professional-guided	Asynchronous	Patient enters data and obtains advice and guidance from professional
Software apps, self-guided	Asynchronous	Patient enters data and obtains advice and self-guidance from the app algorithm

The COVID-19 pandemic dramatically accelerated the adoption and use of telemedicine in an effort to protect patients, providers, and staff. Quickly, video and telephone-based encounters were implemented, and the research from this initial period shows high levels of acceptability from both patients and providers and effectiveness of treatment even when patients switched from in-person to teletherapy, mid-treatment (39). Although this accelerated use occurred in the context of a worldwide pandemic, the benefits of sleep telemedicine have been broadly recognized and will likely remain an alternative option for sleep medicine care (31; 43). As part of a larger randomized non-inferiority trial, patients and providers shared their experiences about telemedicine CBT-I and noted feeling satisfied overall with CBT-I treatment in this modality compared to in-person treatment and appreciated the benefits to access (21). Although sleep telemedicine evolves in the clinical and research setting, focus has also expanded to stress the importance and necessity of adjusting teaching and training to reflect this new standard of care. In a survey of sleep medicine program directors, it was recognized that there was a need to develop a standard telemedicine curriculum to enhance fellows’ training (16), and sleep medicine fellows from the University of Minnesota proposed a model of virtual sleep education to address this gap in training (47).

The AASM makes the distinction between two categories of sleep telemedicine: asynchronous and synchronous. Asynchronous delivery of CBT-I (digital CBT-I, dCBT-I or internet CBT-I, iCBT-I) falls into three distinct modalities of delivery: supportive dCBT-I, therapist-guided dCBT-I, and fully automated dCBT-I (34; 35; 57).

Table 2. Digital CBT-I Programs

dCBT-I programs	Description
CBT-I Coach	Department of Veterans Affairs app
Sleepio	Covered by insurance or employer
Go! To Sleep	Asynchronous 6-week program designed by Cleveland Clinic sleep specialists
Sleep Reset	CBT-I with asynchronous coaching
Stellar Sleep	CBT-I app developed by sleep specialists from Brigham and Women's Hospital and Harvard Medical School

Synchronous telemedicine approaches make use of telehealth for the delivery of sleep medicine via “audio and video two-way, real time, interactive communication.” In this article, we review evidence for and applications of both asynchronous and synchronous telemedicine adaptations of CBT-I. Similar to the stepped-care approaches recommended for in-person delivery of CBT-I (13; 36), delivery of telehealth-delivered CBT-I can range from fully automated to various degrees of therapist assistance (25; 57). Meta-analyses discuss benefits of multiple modalities of both asynchronous and synchronous telehealth-delivered CBT-I as a viable alternative to face-to-face treatment of insomnia (52; 49). Not only do these reviews highlight the effectiveness of this alternative delivery of CBT-I in treating insomnia, but they also stress the promising advances in expanding accessibility and availability of CBT-I worldwide and the associated important public health implications.

Asynchronous. Asynchronous telehealth approaches to CBT-I include communication between patient and provider that does not occur in real-time, if at all. As with synchronous-guided internet-delivered CBT-I, there is a growing body of research supporting the benefits of asynchronous approaches as an alternative to in-person CBT-I treatment that addresses well-documented concerns of access. Using a computer and other electronic devices (cellphone, tablet), digital platforms allow patients to access interactive websites or apps with engaging and informative interfaces that are fully automated and scalable (42). Popular examples of digital CBT-I apps that are empirically supported include Sleepio, SHUTi (Somryst), and CBT-I Coach (12).

In the literature, digital CBT-I is described in various ways, including digital, internet-based, and online. For the purposes of this article, and consistent with recent reviews, the terms “digital” or “dCBT-I” are used (35).

In 2004, Strom and colleagues published the first data of a randomized control trial demonstrating the benefits of digital CBT-I in a self-help format. To date, multiple studies have added to this work and demonstrate that benefits resulting from CBT-I administered via sleep telemedicine modalities are comparable to those delivered during in-person office visits in both adult and pediatric populations (48; 52). These studies have demonstrated improvements in insomnia, sleep quality, pre-sleep cognitive arousal, and dysfunctional beliefs about sleep (58).

Hoping to increase access to insomnia treatment in the primary care setting, Bernstein and colleagues conducted a randomized control trial examining a 6-week, digital, interactive, CBT-based program (Go! To Sleep) designed to foster good sleep practices, sleep restriction, and stimulus control therapies (02). Compared to their control, those who participated in the dCBT-I program demonstrated clinically meaningful improvements in insomnia severity as well as perceived stress that were sustained at 4-month follow-up. Similarly strong support has been demonstrated for SHUT-I (Sleep Healthy Using the Internet), a dCBT-I program. Cancer survivors who completed SHUT-I reported both statistically significant and clinically meaningful improvements in insomnia severity and sleep efficiency compared to a waitlist control (45). Based on this research demonstrating the robust effects of fully automated digital CBT-I on nighttime symptoms, Espie and colleagues expanded their focus to study the effects on daytime functioning and found that engagement in dCBT-I (Sleepio program) was associated with improvement in global health, mental well-being, and sleep-related impairment to quality of life when compared to participation in sleep-hygiene education and that these effects were mediated by insomnia improvements associated with dCBT-I (14). dCBT-I has also been shown to be effective during pregnancy. Kalmbach and colleagues randomized participants to Sleepio or a digital sleep education control (28). (The one modification for the Sleepio arm was that participants were not restricted to less than 6 hours of sleep.) In this study, evidence supported that dCBT-I improves sleep quality and sleep duration during pregnancy and after childbirth. Treatment effects related to depression and cognitive arousal were not observed.

Even for participants experiencing subthreshold insomnia, a randomized control trial studying female participants demonstrated that fully automated dCBT-I (6 weekly CBT-I sessions delivered by an animated “virtual therapist” via the online platform Sleepio) was associated with greater improvements in insomnia compared to a control group as well as improvements in anxiety, paranoia, and perceived stress (08). Fully automated dCBT-I has also been found to be effective for patients with chronic health conditions, including chronic migraines and breast cancer. A 2020 proof of concept study provided evidence that dCBT-I (again, Sleepio) is feasible and acceptable in patients with chronic migraines and insomnia. The treatment was also associated with clinically meaningful responses indicated by reduction in insomnia severity to nonclinical levels and improvement in migraines (05). Similarly, breast cancer survivors who participated in fully automated dCBT-I demonstrated reductions in insomnia severity (that were also clinically significant) and overall improvement in sleep quality (59). It should be noted that in addition to the studies detailed here, this research area continues to grow and expand as indicated by the reporting of new study protocols examining the effectiveness of dCBT-I in different populations, including those with alcohol use disorder (04) and depression (10).

Only a few studies have examined unguided dCBT-I compared to in-person CBT-I. Taylor and colleagues randomized active duty military personnel participants to one of three treatment arms (unguided dCBT-I, in-person CBT-I, and waitlist control) and found that both in-person and unguided dCBT-I were effective interventions and associated with improvements in sleep efficiency, sleep latency, insomnia severity, dysfunctional sleep beliefs, and number of awakenings compared to the control group (53). However, the authors also noted that in-person effect sizes were consistently better than the unguided dCBT-I group, suggesting the importance of triaging care depending on patient needs. Kallestad and colleagues conducted a non-inferiority trial examining fully automated dCBT-I with individual face-to-face CBT-I (26). Although both groups showed significant and clinically meaningful reductions in insomnia severity, participants in the dCBT-I group did not fare as well in reducing sleep medication and long-term dysfunctional beliefs. Because of this, the authors note that with respect to inferiority or non-inferiority, the result is inconclusive, and that future research should aim to focus on the selection of people who would most likely benefit from dCBT-I.

Concern has also been voiced about racial disparities in the real-world uptake and engagement with dCBT-I. Kalmbach and colleagues found racial disparities in treatment engagement and patient-reported outcomes among pregnant women treated with dCBT-I (29). In a round-table discussion on telemedicine and digital delivery of CBT-I, insomnia experts discussed the under-representation of underserved and marginalized populations in the development and testing of this treatment approach as well as the barrier of cost given that digital therapies are often not covered by insurance (27; 37). They agreed that future research should seek to implement a lens of equity when developing and testing these automated dCBT-I platforms. This will be especially critical with the integration of prescription digital therapeutics for insomnia treatment. Somryst is the first (and only, at this time) FDA-approved prescription digital therapeutic for the treatment of insomnia. Originally, SHUT-I, Somryst also has a robust body of research demonstrating that it is an effective treatment modality of dCBT-I for use in asynchronous care. This work is encouraging, and further research may indicate which patients are good candidates for these therapies.

Consistent with the stepped care model of insomnia treatment, asynchronous treatments can also incorporate a therapist/coach who provides feedback, explanations, and encouragement. Among healthy patients, a growing body of literature supports the use of this blended therapy experience through guided CBT-I. dCBT-I offers several advantages, including efficiency of therapist time as well as increased access for patients with daytime responsibilities (work, caretaking) or those with geographical or logistical barriers to coming to clinic in person. van Straten and colleagues demonstrated that guided dCBT-I is feasible, acceptable, and associated with improvements in sleep quality and sleep efficiency, as well as depression, anxiety, and quality of life, when compared to a waitlist control group (56). This same research group compared dCBT-I with and without support and found that motivational support provided via email was associated with sustained benefits for sleep latency, insomnia symptoms, and depressive symptoms (32). Blom and colleagues randomized participants to face-to-face group CBT-I therapy or therapist-guided dCBT-I (03). The therapist-guided digital therapy included active support via written feedback after the participant completed each module. The researchers found that both treatment groups demonstrated significant improvements in insomnia severity (measured by the ISI) from pre- to post-assessments and that these improvements were maintained over a 6-month period. Participants in both treatment groups also showed improvements in secondary outcome measures: sleep latency, efficiency, and sleep quality as well as depression. Moreover, subsequent research has demonstrated that therapist-guided dCBT-I is feasible, well-accepted, and effective for patients with breast cancer (09). As asynchronous treatments can range from fully automated to patient directed, dCBT-I appears to be a viable treatment option that is wide-ranging and acceptable for patients who might not otherwise have access to this treatment. Triaging specific needs and determining which patients will benefit from more or less assistance and guidance is an important area of future research.

Synchronous. Synchronous telemedicine approaches to CBT-I require the patient and therapist to be interacting at the same time. This method offers the benefit of communicating directly with a therapist without the burden of having to travel to a clinic. Similar to the state of the science on asynchronous approaches, the research literature focusing on synchronous telehealth approaches to CBT-I is rapidly expanding. In an interesting effort to determine which CBT-I modality to offer in their clinic, Holmqvist and colleagues compared the impact of a six-session CBT-I intervention for rural dwelling adults offered either through a digital platform (asynchronous) or telehealth (synchronous) (24). Participants who were randomized to the telehealth arm were included as members of an in-person treatment group. Their findings indicated that both interventions were effective in producing meaningful change, including improvements in insomnia severity, fatigue, and work and social impairment. Over the course of the study, participants in both groups also reduced their use of sedating medications. Telehealth delivery of group CBT-I has also been examined as part of the VA’s National Telemental Health Program and CBT-I dissemination efforts. Gehrman and colleagues found that telehealth delivery of group CBT-I is not only feasible in a VAMC setting but also scalable as evidenced by its use in other locations without diminishing effectiveness or acceptability (19). In a 2020 study, this same research group found that for veterans with posttraumatic stress disorder, delivery of CBT-I by clinical video telehealth was non-inferior to in- person treatment (17).

Telehealth CBT-I for individual treatment also has empirical support. Rural dwelling, middle-aged to older adults who participated in integrated telehealth-delivered CBT-I and CBT-D (cognitive behavioral therapy for depression) reported significant reductions in insomnia severity compared to those who received care as usual. Furthermore, these reductions in insomnia severity were clinically significant, with a majority of participants not meeting diagnostic criteria for insomnia at the end of the study. In an earlier stage of this study, this same research group established that rural-dwelling participants were engaged in the intervention and found telehealth-delivered CBT-I to be an acceptable modality of treatment (33). Similarly, McCarthy and colleagues conducted a pilot study that demonstrated that telemedicine-delivered CBT-I (six sessions) is feasible and acceptable for breast cancer survivors living in rural areas (40). Participation in treatment was also associated with improvements in sleep efficiency, sleep latency, insomnia severity, and increase in quality of life and daytime functioning. Researchers found similar results in a pilot study that assessed the feasibility and treatment effect of tele-CBT-I in participants diagnosed with multiple sclerosis (55). In addition to demonstrating that the treatment is feasible (retention and adherence rates were 100%), participants experienced improvements in sleep quality, insomnia severity, fatigue, sleep latency, sleep self-efficacy, depression, and quality of life.

In a novel application of synchronous telehealth treatment, Gieselmann and Pietrowsky conducted a waitlist control study examining the effects of a brief three-session treatment for insomnia, delivered in-person or through synchronous text-based chats (20). Their findings suggest that the chat-based insomnia treatment was as effective as face-to-face treatment for sleep quality and outperformed face-to-face treatment on subjective total sleep time, depression, anxiety, and pre-sleep cognitive arousal. The researchers suggest that the potential benefits of chat-based treatment include focus, sense of responsibility, as well as autonomy.

Non-inferiority trials. Gehrman and colleagues demonstrated that a synchronous telehealth approach produces clinically significant improvements in insomnia severity that are non-inferior to in-person treatment (18). Specifically, they found that CBT-I delivered via telehealth is not clinically inferior to in-person treatment and is superior to a waitlist control. Participants in both treatment groups reported improved insomnia severity compared to the control group, which was maintained at the 3-month follow-up. There were also significant improvements in mood/anxiety and daytime functioning for the two treatment groups compared to the control group. Arnedt and colleagues observed similar post-treatment effects in their study that randomly assigned participants to either six sessions face-to-face or telehealth CBT-I (01). They found sustained improvements in insomnia, fatigue, depression and anxiety symptoms, sleep-related cognitions, and quality of life for both groups. Of note, therapeutic alliance ratings were also similar regardless of whether treatment was in person or via telehealth. Similar effectiveness of synchronous telehealth has also been observed in real-world settings during the COVID-19 pandemic. Martin and colleagues examined how veterans fared in the transition from face-to-face CBT-I to telehealth delivery of CBT-I and found that CBT-I remained highly effective, regardless of treatment modality (39). Taken together, these findings lay the foundation for the use of synchronous telehealth-delivered CBT-I as a promising alternative to in-person treatment that has the potential to produce similar improvements in sleep health and patient-centered care.

Conclusion

Cognitive behavioral therapy for insomnia (CBT-I) is considered a first-line treatment for chronic insomnia. Sleep telemedicine approaches (asynchronous and synchronous) can help to close the gap between clinical research and clinical care and offers an important and promising alternative to expanding care and optimizing sleep health. The studies referenced here indicate that both asynchronous and synchronous telehealth deliveries of CBT-I are effective and have the potential to address long-standing issues of CBT-I dissemination and provide access to care for a greater number of individuals without sacrificing clinical effectiveness. This is an important and growing area of research. Given the many different options for telehealth delivery of CBT-I that all demonstrate promising clinical effectiveness, future research will ideally seek to determine how to best personalize treatment to meet patient needs with equity, efficiency, and effectiveness.

References

01: Arnedt JT, Conroy DA, Mooney A, Furgal A, Sen A, Eisenberg D. Telemedicine versus face-to-face delivery of cognitive behavioral therapy for insomnia: a randomized controlled noninferiority trial. Sleep 2021;44(1):zsaa136. PMID 32658298
02: Bernstein AM, Allexandre D, Ben J, et al. “Go! To Sleep”: a web-based therapy for insomnia. Telemed J E Health 2017;23(7):590-9. PMID 28112590
03: Blom K, Tillgren HT, Wiklund T, et al. Internet-vs. group-delivered cognitive behavior therapy for insomnia: a randomized controlled non-inferiority trial. Behav Res Ther 2015;70:47-55. PMID 25981329
04: Brooks AT, Tuason RT, Chakravorty S, et al. Online cognitive behavioral therapy for insomnia (CBT-I) for the treatment of insomnia among individuals with alcohol use disorder: study protocol for a randomized controlled trial. Pilot Feasibility Stud 2018;4:183. PMID 30555713
05: Crawford MR, Luik AI, Espie CA, et al. Digital cognitive behavioral therapy for insomnia in women with chronic migraines. Headache 2020;60(5):902-15. PMID 32112436
06: Cuthbert K, Parsons EM, Smith L, Otto MW. Acceptability of telehealth CBT during the time of COVID-19: evidence from patient treatment initiation and attendance records. J Behav Cogn Ther 2022;32(1):67-72. PMID 35018352
07: Daley M, Morin CM, LeBlanc M, Grégoire JP, Savard J, Baillargeon L. Insomnia and its relationship to health-care utilization, work absenteeism, productivity and accidents. Sleep Med 2009;10(4):427-38. PMID 18753000
08: Denis D, Eley TC, Rijsdijk F, et al. Is digital cognitive behavioural therapy for insomnia effective in treating sub-threshold insomnia: a pilot RCT. Sleep Med 2020;66:174-83. PMID 31901759
09: Dozeman E, Verdonck-de Leeuw IM, Savard J, van Straten A. Guided web-based intervention for insomnia targeting breast cancer patients: feasibility and effect. Internet Interv 2017;9:1-6. PMID 30135831
10: Drake CL, Kalmbach DA, Cheng P, et al. Sleep to Reduce Incident Depression Effectively (STRIDE): study protocol for a randomized controlled trial comparing stepped-care cognitive-behavioral therapy for insomnia versus sleep education control to prevent major depression. Trials 2022;23(1):967. PMID 36457045
11: Edinger JD, Arnedt JT, Bertisch SM, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine 2021;17(2):255-62. PMID 33164742
12: Erten Uyumaz B, Feijs L, Hu J. A review of digital cognitive behavioral therapy for insomnia (CBT-I Apps): are they designed for engagement? Int J Environ Res Public Health 2021;18(6):2929. PMID 33809308
13: Espie CA. “Stepped care”: a health technology solution for delivering cognitive behavioral therapy as a first line insomnia treatment. Sleep 2009;32(12):1549-58. PMID 20041590
14: Espie CA, Emsley R, Kyle SD, et al. Effect of digital cognitive behavioral therapy for insomnia on health, psychological well-being, and sleep-related quality of life: a randomized clinical trial. JAMA Psychiatry 2019;76(1):21-30. PMID 30264137
15: Fernandez E, Woldgabreal Y, Day A, Pham T, Gleich B, Aboujaoude E. Live psychotherapy by video versus in‐person: a meta‐analysis of efficacy and its relationship to types and targets of treatment. Clin Psychol 2021;28(6):1535-49. PMID 33826190
16: Fields BG, Dholakia SA, Ioachimescu OC. Sleep telemedicine training in fellowship programs: a survey of program directors. J Clin Sleep Med 2020;16(4):575-81. PMID 32022680
17: Gehrman P, Barilla H, Medvedeva E, Bellamy S, O'Brien E, Kuna ST. Randomized trial of telehealth delivery of cognitive-behavioral treatment for insomnia vs. in-person treatment in veterans with PTSD. Journal of Affective Disorders Reports 2020;1:100018.
18: Gehrman P, Gunter P, Findley J, et al. Randomized noninferiority trial of telehealth delivery of cognitive behavioral treatment of insomnia compared to in-person care. J Clin Psychiatry 2021;82(5):20m13723. PMID 34428360
19: Gehrman P, Shah MT, Miles A, Kuna S, Godleski L. Feasibility of group cognitive-behavioral treatment of insomnia delivered by clinical video telehealth. Telemed J E Health 2016;22(12):1041-6. PMID 27286369
20: Gieselmann A, Pietrowsky R. The effects of brief chat-based and face-to-face psychotherapy for insomnia: a randomized waiting list controlled trial. Sleep Med 2019;61:63-72. PMID 31262551
21: Granberg RE, Heyer A, Gehrman PR, et al. Patient and provider experiences with CBT-I administered in-person or via telemedicine: a randomized non-inferiority trial. Cogent Psychology 2022;9(1):2038936.
22: Gros DF, Morland LA, Greene CJ, et al. Delivery of evidence-based psychotherapy via video telehealth. Journal of Psychopathology and Behavioral Assessment 2013;35:506-21.
23: Ho FY, Chung KF, Yeung WF, et al. Self-help cognitive-behavioral therapy for insomnia: a meta-analysis of randomized controlled trials. Sleep Med Rev 2015;19:17-28. PMID 25104471
24: Holmqvist M, Vincent N, Walsh K. Web-vs. telehealth-based delivery of cognitive behavioral therapy for insomnia: a randomized controlled trial. Sleep Med 2014;15(2):187-95. PMID 24461370
25: Hsieh C, Rezayat T, Zeidler MR. Telemedicine and the management of insomnia. Sleep Med Clin 2020;15(3):383-90. PMID 32762971
26: Kallestad H, Scott J, Vedaa Ø, et al. Mode of delivery of cognitive behavioral therapy for insomnia: a randomized controlled non-inferiority trial of digital and face-to-face therapy. Sleep 2021;44(12):zsab185. PMID 34291808
27: Kalmbach DA, Cheng P. Embracing telemedicine and digital delivery of cognitive-behavioral therapy for insomnia: where do we come from and where are we going? Sleep 2023;46(1):zsac291. PMID 36455233
28: Kalmbach DA, Cheng P, O'Brien LM, et al. A randomized controlled trial of digital cognitive behavioral therapy for insomnia in pregnant women. Sleep Med 2020;72:82-92. PMID 32559716
29: Kalmbach DA, Cheng P, Reffi AN, et al. Racial disparities in treatment engagement and outcomes in digital cognitive behavioral therapy for insomnia among pregnant women. Sleep Health 2023;9(1):18-25. PMID 36456448
30: Koffel E, Bramoweth AD, Ulmer CS. Increasing access to and utilization of cognitive behavioral therapy for insomnia (CBT-I): a narrative review. J Gen Intern Med 2018;33(6):955-62. PMID 29619651
31: Kryger M, Goldstein CA. COVID-19 and sleep. In: Kryger MH, Roth T, Goldstein CA, editors. Principles and Practice of Sleep Medicine. Elsevier, 2021:199-2010.e6.
32: Lancee J, van den Bout J, Sorbi MJ, van Straten A. Motivational support provided via email improves the effectiveness of internet-delivered self-help treatment for insomnia: a randomized trial. Behav Res Ther 2013;51(12):797-805. PMID 24121097
33: Lichstein KL, Scogin F, Thomas SJ, DiNapoli EA, Dillon HR, McFadden A. Telehealth cognitive behavior therapy for co‐occurring insomnia and depression symptoms in older adults. J Clin Psychol 2013;69(10):1056-65. PMID 24014056
34: Luik AI, Kyle SD, Espie CA. Digital cognitive behavioral therapy (dCBT) for insomnia: a state-of-the-science review. Curr Sleep Med Rep 2017;3(2):48-56. PMID 28553574
35: Luik AI, van der Zweerde T, van Straten A, Lancee J. Digital delivery of cognitive behavioral therapy for insomnia. Curr Psychiatry Rep 2019;21(7):50. PMID 31161406
36: Mack LJ, Rybarczyk BD. Behavioral treatment of insomnia: a proposal for a stepped-care approach to promote public health. Nat Sci Sleep 2011;3:87-99. PMID 23616720
37: Manber R, Alcántara C, Bei B, Morin CM, van Straten AA. Integrating technology to increase the reach of CBT-I: state of the science and challenges ahead. Sleep 2023;46(1):zsac252. PMID 36308320
38: Manber R, Simpson NS, Bootzin RR. A step towards stepped care: delivery of CBT-I with reduced clinician time. Sleep Med Rev 2015;19:3-5. PMID 25454675
39: Martin JL, DeViva J, McCarthy E, et al. In-person and telehealth treatment of veterans with insomnia disorder using cognitive behavioral therapy for insomnia during the COVID-19 pandemic. J Clin Sleep Med 2023;19(7):1211-7. PMID 36859803
40: McCarthy MS, Matthews EE, Battaglia C, Meek PM. Feasibility of a telemedicine-delivered cognitive behavioral therapy for insomnia in rural breast cancer survivors. Oncol Nurs Forum 2018;45(5):607-18. PMID 30118453
41: Morin CM. Profile of Somryst prescription digital therapeutic for chronic insomnia: overview of safety and efficacy. Expert Rev Med Devices 2020;17(12):1239-48. PMID 33226269
42: Muench A, Vargas I, Grandner MA, et al. We know CBT-I works, now what? Fac Rev 2022;11:4. PMID 35156100
43: Nicosia FM, Kaul B, Totten AM, et al. Leveraging telehealth to improve access to care: a qualitative evaluation of veterans’ experience with the VA TeleSleep program. BMC Health Serv Res 2021;21(1):77. PMID 33478497
44: Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD, Clinical Guidelines Committee of the American College of Physicians. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2016;165(2):125-33.** PMID 27136449
45: Ritterband LM, Bailey ET, Thorndike FP, Lord HR, Farrell‐Carnahan L, Baum LD. Initial evaluation of an Internet intervention to improve the sleep of cancer survivors with insomnia. Psychooncology 2012;21(7):695-705. PMID 21538678
46: Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med 2007;3(5 suppl):S7-10. PMID 17824495
47: Ryba-White B, Gupta S, Khalil W, Irfan M. Integrating telemedicine into sleep medicine: a learner’s perspective. J Clin Sleep Med 2021;17(12):2573-6. PMID 34170237
48: Seyffert M, Lagisetty P, Landgraf J, et al. Internet-delivered cognitive behavioral therapy to treat insomnia: a systematic review and meta-analysis. PloS One 2016;11(2):e0149139. PMID 26867139
49: Sharafkhaneh A, Salari N, Khazaie S, et al. Telemedicine and insomnia: a comprehensive systematic review and meta-analysis. Sleep Med 2022;90:117-30. PMID 35151065
50: Simon L, Steinmetz L, Feige B, Benz F, Spiegelhalder K, Baumeister H. Comparative efficacy of onsite, digital, and other settings for cognitive behavioral therapy for insomnia: a systematic review and network meta-analysis. Sci Rep 2023;13(1):1929. PMID 36732610
51: Smith MT, Perlis ML. Who is a candidate for cognitive-behavioral therapy for insomnia? Health Psychol 2006;25(1):15-9. PMID 16448293
52: Soh HL, Ho RC, Ho CS, Tam WW. Efficacy of digital cognitive behavioural therapy for insomnia: a meta-analysis of randomised controlled trials. Sleep Med 2020;75:315-25. PMID 32950013
53: Taylor DJ, Peterson AL, Pruiksma KE, et al. Internet and in-person cognitive behavioral therapy for insomnia in military personnel: a randomized clinical trial. Sleep 2017;40(6). PMID 28472528
54: Thomas A, Grandner M, Nowakowski S, Nesom G, Corbitt C, Perlis ML. Where are the behavioral sleep medicine providers and where are they needed? A geographic assessment. Behav Sleep Med 2016;14(6):687-98. PMID 27159249
55: Turkowitch D, Ludwig R, Nelson E, Drerup M, Siengsukon CF. Telehealth-delivered cognitive behavioral therapy for insomnia in individuals with multiple sclerosis: a pilot study. Mult Scler Int 2022;2022:7110582. PMID 35281348
56: van Straten A, Emmelkamp J, De Wit J, et al. Guided Internet-delivered cognitive behavioural treatment for insomnia: a randomized trial. Psychol Med 2014;44(7):1521-32. PMID 24001364
57: Vedaa O, Miller KE, Gehrman PR. Behavioral treatment III: digital and telehealth approaches. In: Kryger MH, Roth T, Goldstein CA, editors. Principles and Practice of Sleep Medicine. Elsevier, 2021:896-901e.4.
58: Vincent N, Lewycky S. Logging on for better sleep: RCT of the effectiveness of online treatment for insomnia. Sleep 2009;32(6):807-15. PMID 19544758
59: Zachariae R, Amidi A, Damholdt MF, et al. Internet-delivered cognitive-behavioral therapy for insomnia in breast cancer survivors: a randomized controlled trial. J Natl Cancer Inst 2018;110(8):880-7. PMID 29471478
60: References especially recommended by the author or editor for general reading.

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Skye Margolies PhD

Dr. Margolies of UNC School of Medicine has no relevant financial relationships to disclose.
See Profile

Editor

Bradley V Vaughn MD

Dr. Vaughn of UNC Hospital Chapel Hill and University of North Carolina School of Medicine has no relevant financial relationships to disclose.
See Profile

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Telehealth and cognitive behavioral therapy for insomnia (CBT-I0)

Also Relevant

Insomnia
Psychophysiological insomnia

Clinical Categories

Sleep Disorders

Patient Handouts

Insomnia

Telehealth and cognitive behavioral therapy for insomnia …

Telehealth and cognitive behavioral therapy for insomnia (CBT-I0)

Introduction

Overview

Key points

Discussion

Sleep telemedicine

Table 1. Types of TeleHealth and Telemedicine

Table 2. Digital CBT-I Programs

Conclusion

References

Contributors

Author

Editor

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Hypersomnolence

Fatal familial insomnia

Sleep and mental disorders

Sleep paralysis

Sleep and epilepsy

Narcolepsy

Confusional arousal

Restless legs syndrome

Telehealth and cognitive behavioral therapy for insomnia (CBT-I0)

Introduction

Overview

Key points

Discussion

Sleep telemedicine

Table 1. Types of TeleHealth and Telemedicine

Table 2. Digital CBT-I Programs

Conclusion

References

Contributors

Author

Editor

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Hypersomnolence

Fatal familial insomnia

Sleep and mental disorders

Sleep paralysis

Sleep and epilepsy

Narcolepsy

Confusional arousal

Restless legs syndrome

This is an article preview.
Start a Free Account
to access the full version.